To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

The study is intended to assess the pharmacokinetics (PK), proprotein convertase subtilisin/kexin type 9 (PCSK9) reduction, safety and tolerability of AZD8233 in male and female participants with severe renal impairment and participants with ESRD compared to matched healthy control participants.

This is an open-label, single dose, non-randomised, parallel group study. Participant will be enrolled in 3 cohorts. * Cohort 1 will include 8 participants with severe renal impairment (estimated glomerular filtration rate \[eGFR\] of ≥15 to \< 30 mL/min/1.73 m\^2). * Cohort 2 will include 8 healthy participants with normal renal function (eGFR of ≥ 90 mL/min/1.73 m\^2) that will serve as matched controls for Cohort 1 and Cohort 3. Matching will account for age, Body mass index (BMI), and gender. * Cohort 3 will include 8 participants with ESRD on dialysis (eGFR of \< 15 mL/min/1.73 m\^2). * Participants in Cohort 3 will receive a single dose of AZD8233 the day after haemodialysis. Participant will receive the study drug on Day 1, discharged on Day 2 followed by out-patient follow-up visits on Day 3, 7, 14, 28, 42, 56, and 90.